| Drug General Information |
| Drug ID |
D0E7VO
|
| Former ID |
DIB019413
|
| Drug Name |
compound 2c
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C19H20FN7O
|
| InChI |
InChI=1S/C19H20FN7O/c1-11(2)28-18-8-17(25-26-18)27-10-22-15-6-7-16(24-19(15)27)23-12(3)14-5-4-13(20)9-21-14/h4-12H,1-3H3,(H,23,24)(H,25,26)/t12-/m0/s1
|
| InChIKey |
FZBVNCFBCNXULH-LBPRGKRZSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Trk receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| WNK lysine deficient protein kinase 3 |
Target Info |
Inhibitor |
[1]
|
| phosphorylase kinase, gamma 2 (testis) |
Target Info |
Inhibitor |
[1]
|
| FGR proto-oncogene, Src family tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
| mRNA of Abl |
Target Info |
Inhibitor |
[1]
|
| Tyrosine-protein kinase BTK |
Target Info |
Inhibitor |
[1]
|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[1]
|
| testis-specific serine kinase 2 |
Target Info |
Inhibitor |
[1]
|
| salt-inducible kinase 1 |
Target Info |
Inhibitor |
[1]
|
| FL cytokine receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditishsa04064:NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Primary immunodeficiencyhsa04010:MAPK signaling pathway
|
|
Rap1 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Proteoglycans in cancer
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancerhsa04060:Cytokine-cytokine receptor interaction
|
|
Hematopoietic cell lineage
|
|
Transcriptional misregulation in cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Axon guidance mediated by Slit/RoboP00010:B cell activationP00005:Angiogenesis
|
|
FGF signaling pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
PDGFR-beta signaling pathway
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma proteinfcer1pathway:Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
FAS (CD95) signaling pathway
|
|
Class I PI3K signaling events
|
|
EPO signaling pathwayglypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathway
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
ARMS-mediated activation
|
|
NGF-independant TRKA activation
|
|
PI3K/AKT activationR-HSA-2029482:Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-166058:MyD88:Mal cascade initiated on plasma membrane
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
DAP12 signaling
|
|
FCERI mediated Ca+2 mobilization
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
MAPK Signaling Pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
NGF signalling via TRKA from the plasma membraneWP710:DNA Damage Response (only ATM dependent)
|
|
DNA Damage Response
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet production
|
|
TP53 Network
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage ResponseWP304:Kit receptor signaling pathway
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Signaling by the B Cell Receptor (BCR)
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling PathwayWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Signaling Pathways in Glioblastoma
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
| References |
| REF 1 | Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. |
|---|
